Want to see RLMD full AI Analyst Report?
RLMD Stock Chart & Stats
$5.18
-$0.02(-0.38%)
At close: 4:00 PM EDT
$5.18
-$0.02(-0.38%)
Day’s Range― - ―
52-Week Range$0.56 - $8.00
Previous CloseN/A
Volume1.65M
Average Volume (3M)2.33M
Market Cap
$476.81M
Enterprise Value$559.91
Total Cash (Recent Filing)$217.73M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Nov 05, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding106,669,846
10 Day Avg. Volume1,903,216
30 Day Avg. Volume2,328,641
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.20
Price to Sales (P/S)0.00
P/FCF Ratio-4.16
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.33Price Target Upside176.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.83
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Runway / LiquidityA materially strengthened cash position that management expects to fund operations through 2029 provides durable financial flexibility to finish pivotal activities. This liquidity reduces near‑term solvency risk, allows completion of Phase III planning and IND filings, and lowers immediate financing pressure.
Clinical Efficacy & Regulatory AlignmentCompelling 12‑month Phase II efficacy with favorable safety and explicit FDA alignment materially strengthens the registrational case for NDV‑01. Durable clinical results plus regulatory pathway clarity reduce regulatory execution risk and improve the structural probability of successful Phase III design and approval.
Experienced Commercial LeadershipAdding an experienced CBO with prior uro‑oncology launch experience enhances long‑term commercialization planning, business development and strategic execution. This leadership upgrade strengthens commercial preparedness and deal‑making capability ahead of potential Phase III success and market entry.
Bears Say
Pre‑revenue Cash BurnRelmada remains a pre‑commercial biotech with substantial negative operating cash flow and net losses. Persistent burn without product revenues means ongoing reliance on cash reserves or future financings, creating structural dilution and budgeting risks if development timelines or costs extend beyond current plans.
Manufacturing / CMC Execution RiskNDV‑01 advancement is gated by GMP scale‑up and stability data from a contract manufacturer. Reliance on external CMO scheduling and successful GMP runs creates a durable execution risk that can delay IND filings, increase costs, and push back registrational timelines, materially affecting program delivery.
Dilution / Capital‑Raise FlexibilityThe authorized‑share increase structurally expands management's capacity to issue equity for financing or compensation. Coupled with ongoing losses and potential future funding needs to support Phase III and manufacturing, this governance change raises the likelihood of shareholder dilution over the medium term.
Relmada Therapeutics News
RLMD FAQ
What was Relmada Therapeutics Inc’s price range in the past 12 months?
Relmada Therapeutics Inc lowest stock price was $0.56 and its highest was $8.00 in the past 12 months.
What is Relmada Therapeutics Inc’s market cap?
Relmada Therapeutics Inc’s market cap is $476.81M.
When is Relmada Therapeutics Inc’s upcoming earnings report date?
Relmada Therapeutics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 84 days.
How were Relmada Therapeutics Inc’s earnings last quarter?
Relmada Therapeutics Inc released its earnings results on Aug 06, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.09.
Is Relmada Therapeutics Inc overvalued?
According to Wall Street analysts Relmada Therapeutics Inc’s price is currently Undervalued.
Does Relmada Therapeutics Inc pay dividends?
Relmada Therapeutics Inc does not currently pay dividends.
What is Relmada Therapeutics Inc’s EPS estimate?
Relmada Therapeutics Inc’s EPS estimate is -0.14.
How many shares outstanding does Relmada Therapeutics Inc have?
Relmada Therapeutics Inc has 106,669,846 shares outstanding.
What happened to Relmada Therapeutics Inc’s price movement after its last earnings report?
Relmada Therapeutics Inc reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went down -8.007%.
Which hedge fund is a major shareholder of Relmada Therapeutics Inc?
Currently, no hedge funds are holding shares in RLMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Relmada Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.33 (176.71% Upside)
$14.33 (176.71% Upside)
Blogger Sentiment
Bullish
RLMD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
678.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
937.40%
Trailing 12-Months
Company Description
Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
RLMD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed a constructive and execution-focused tone: Relmada reported a materially strengthened balance sheet (cash +134% YoY) with a cash runway into 2029, compelling 12-month Phase II efficacy and favorable safety for NDV-01, clear FDA-aligned registration pathways, an experienced new CBO, and engaged clinical sites. Key near-term risks center on manufacturing/CMC execution (GMP batch production and stability data), which shifted IND timing toward year-end 2026 and has increased R&D spend and operating cash use. On balance the company appears well-capitalized and positioned to advance registrational programs, but outcomes hinge on resolving manufacturing scale-up and timing.View all RLMD earnings summariesRLMD Stock 12 Month Forecast
Average Price Target
$14.33
▲(176.71% Upside)
Technical Analysis
Ownership Overview
2.82% Insiders
3.68% Mutual Funds
2.49% Other Institutional Investors
79.80% Public Companies and
Individual Investors